This retrospective study will evaluate characteristics, vaccine utilization and outcomes among subjects with immunocompromising conditions that received COVID-19 vaccination.
The objective of this US-based retrospective cohort study is to evaluate characteristics,
vaccine utilization and outcomes among subjects with immunocompromising conditions that
received COVID-19 vaccination.
Subjects will be aged 12 years and older and will have no evidence of prior SARS-CoV-2
infection.
The primary analysis will be conducted on subjects vaccinated with BNT162b2.
A variety of subgroup analyses and sensitivity analyses are planned.
Biological: BNT162b2 (Tozinameran)
Covid-19 Vaccine
Other Name: Pfizer-BioNTech COVID-19 vaccine
Inclusion Criteria:
Patients must meet all of the following inclusion criteria to be eligible for inclusion in
the study:
1. Unique enrollees in the HealthVerity Vaccine dataset anytime after December 10, 2020
2. At least 12 years on the index date (ie, first vaccination date)
3. No evidence of prior COVID-19 infection (a medical claim, pharmacy claim, or
chargemaster record with a diagnosis code of ICD-10-CM U07.1) in the 12 months prior
to the index date
4. Have 12 months of continuous enrollment with medical benefits (with or without
pharmacy benefits) prior to the index date.
Subjects with an IC condition will be identified via an algorithm developed for use in
administrative claims database studies.
Exclusion criteria: subjects not meeting the criteria above will be excluded.
Pfizer Inc.
New York, New York, United States
Pfizer CT.gov Call Center, Study Director
Pfizer